Skip to main content

Advertisement

SpringerLink
Log in

Safety and efficacy of secukinumab in psoriasis patients infected with hepatitis B virus: a retrospective study

  • Therapy
  • Published:
European Journal of Dermatology

Abstract

Background

The burden of hepatitis B virus (HBV) infection in China is high. The safety and efficacy of secukinumab in psoriasis patients with HBV infection have not been fully elucidated.

Objectives

To investigate the safety and efficacy of secukinumab in psoriasis patients with HBV infection in China.

Materials & Methods

In this retrospective study, 20 psoriasis patients with HBV infection were identified, all of whom had been treated with secukinumab for ≥24 weeks

Results

Four patients had chronic inactive HBV infection, two patients had occult HBV infection, and the other 14 patients had resolved HBV infection. The HBV-DNA load and HBV markers measured at baseline and Week 24 showed no viral reactivation. Nineteen patients showed normal levels of liver enzymes after 24 weeks of therapy. However, one patient with resolved HBV infection and fatty liver with elevated baseline liver enzymes experienced hepatitis, with negative HBV load at baseline and Week 24. All patients showed a significant improvement in the Psoriasis Area and Severity Index (−13.35 ± 7.41: p < 0.0001), per cent of body surface area (−17.11 ± 17: p = 0.0002), Investigator Global Assessment (−2.55 ± 0.94: p < 0.0001), and Dermatology Life Quality Index (−12.3 ± 7.39; p < 0.0001)

Conclusion

Secukinumab showed good efficacy in psoriasis patients with HBV infection. Chronic, inactive, occult and resolved HBV infection may not increase the risk of hepatitis during secukinumab treatment. Patients with poor baseline liver function, without any intervention during secukinumab treatment, may experience hepatitis. Periodic monitoring with HBV markers, HBV-DNA load, and serological liver function tests is necessary during secukinumab treatment

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007; 25: 53546.

    Article  Google Scholar 

  2. Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf 2016; 15: 1413–20.

    Article  CAS  PubMed  Google Scholar 

  3. Lonnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol 2014; 7: 251–9.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Sanford M, McKeage K. Secukinumab: first global approval. Drugs 2015; 75: 329–38.

    Article  CAS  PubMed  Google Scholar 

  5. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014; 14: 585–600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bao S, Zheng J, Shi G. The role of T helper 17 cells in the pathogenesis of hepatitis B virus-related liver cirrhosis (Review). Mol Med Rep 2017; 16: 3713–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384: 205343.

    Article  Google Scholar 

  8. Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. Psoriasis 2017; 7: 35–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wang H, Men P, Xiao Y, et al. Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis 2019; 19: 811.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Manalo IF, Gilbert KE, Wu JJ. Preventing hepatitis B reactivation associated with immunosuppressive drug treatments for psoriasis. J Am Acad Dermatol 2015; 73: 881–2.

    Article  PubMed  Google Scholar 

  11. Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol 2017; 77: 88–97.e85.

    Article  PubMed  Google Scholar 

  12. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156–165.

    Article  CAS  PubMed  Google Scholar 

  13. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med 2014; 371: 326–38.

    Article  PubMed  Google Scholar 

  14. Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015; 73: 400–9.

    Article  CAS  PubMed  Google Scholar 

  15. Raimondo A, Balato A, Megna M, Balato N. Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future. Expert Opin Biol Ther 2018; 18: 605–7.

    Article  CAS  PubMed  Google Scholar 

  16. Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 774–90.

    Article  CAS  PubMed  Google Scholar 

  17. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 2019; 80: 2740.

    Article  Google Scholar 

  18. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol 2019; 80: 43–53.

    Article  PubMed  Google Scholar 

  19. van Denderen JC, Blom GJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept. Clin Rheumatol 2012; 31: 1677–82.

    Article  CAS  PubMed  Google Scholar 

  20. Beringer A, Miossec P. IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases. Autoimmun Rev 2018; 17: 1176–85.

    Article  CAS  PubMed  Google Scholar 

  21. Chiu HY, Hui RC, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study. Acta Derm Venereol 2018; 98: 829–34.

    Article  CAS  PubMed  Google Scholar 

  22. Yanagihara S, Sugita K, Yoshida Y, Tsuruta D, Yamamoto O. Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy. Eur J Dermatol 2017; 27: 185–6.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The patients in this manuscript have given written informed consent to publication of their case details.

Funding

This work was sponsored by grants from National Natural Science Foundation of China (No. 81872522, 82073429, 82003334), Innovation Program of Shanghai Municipal Education Commission (No.2019-01-07-00-07-E00046), the Program of Science and Technology Commission of Shanghai Municipality (No. 18140901800), Excellent Subject Leader Program of Shanghai Municipal Commission of Health and Family Planning (No. 2018BR30), Clinical Research Program of Shanghai Hospital Development Center (No. SHDC2020CR1014B, SHDC12018X06) and Program of Shanghai Academic Research Leader (No. 20XD1403300), Shanghai Health and Family Planning Commission (201840365).

Author information

Author notes

  1. These authors contributed equally

Authors and Affiliations

  1. Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China

    Hui Qin, Na Liu, Yifan Hu, Ning Yu, Xuemei Yi, Yunlu Gao, Fujuan Chen, Yangfeng Ding & Yuling Shi

  2. Institue of Psoriasis, Tongji University School of Medicine, Shanghai, China

    Hui Qin, Na Liu, Yifan Hu, Ning Yu, Xuemei Yi, Yunlu Gao, Fujuan Chen, Jun Gu, Yangfeng Ding & Yuling Shi

  3. Department of Dermatology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China

    Yifan Hu & Jun Gu

Authors
  1. Hui Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Na Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yifan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ning Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xuemei Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yunlu Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fujuan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jun Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yangfeng Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yuling Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hui Qin, Yangfeng Ding or Yuling Shi.

Additional information

Conflicts of interest

none.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qin, H., Liu, N., Hu, Y. et al. Safety and efficacy of secukinumab in psoriasis patients infected with hepatitis B virus: a retrospective study. Eur J Dermatol 32, 394–400 (2022). https://doi.org/10.1684/ejd.2022.4263

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2022.4263

Key words

Search

Navigation